Skip to main
REPL
REPL logo

REPL Stock Forecast & Price Target

REPL Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 38%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

Replimune Group Inc has increased its probability of approval for its RP1 + Opdivo treatment in anti-PD1 failed melanoma patients to 85%, indicating strong confidence in its clinical outcomes. The favorable safety profile of RP1 + Opdivo, with only 12.8% of patients experiencing G3+ treatment-related adverse events, further supports its potential for regulatory approval. Given the promising trial results, Replimune is positioned well in the market, with performance metrics indicative of a strong future for its oncolytic immunotherapies pipeline.

Bears say

Replimune Group Inc faces several significant risks that contribute to a negative outlook on its stock, particularly surrounding its product candidate RP1, which is currently under scrutiny by the FDA due to concerns regarding the adequacy of clinical trial data and the effectiveness of the trial design. The company may struggle to generate compelling efficacy and safety data, and any failure to meet regulatory requirements for marketing authorization could impede its progress and threaten long-term viability. Additionally, the potential for medium- to long-term dilution presents further financial risks, as does the uncertainty regarding the early-stage pipeline of oncolytic virus candidates.

REPL has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 38% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Replimune Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Replimune Group Inc (REPL) Forecast

Analysts have given REPL a Buy based on their latest research and market trends.

According to 8 analysts, REPL has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Replimune Group Inc (REPL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.